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Traumatic injury remains the leading cause of death with bleeding in the world, repre-
senting the main cause of preventable death. But if immediate management could be
applied, the outcomes will be dramatically improved. Trauma-induced coagulopathy
(TIC) as an early endogenous process in many traumatic patients is driven by the multi-
tissue injury and shock, and is associated with increased mortality and bad outcomes in
the multi-trauma patients. The understanding of the mechanisms of TIC and its effect on
the outcomes of severely injured patients has been developed over the past few years.
Here, we aim to review the current understanding and recent ﬁndings in the pathobiology
of coagulopathy. The principal causes of TIC are hypoperfusion, inﬂammation response
and the activation of the neurohumoral system. Hypoperfusion causes the activation of
many biomarkers, like protein C, syndecan-1, plasminogen, and so on. The elevation of
these markers indicates the damage of the endothelium, which will lead to autohepari-
nization in body. When accompanied with acidosis, hypothermia, and hemodilution, the
mortality of trauma patients will rise signiﬁcantly. This article aims to focus on our
updated acknowledges on the principal mechanisms and causes of the TIC.1. Introduction
Trauma is a major cause of deaths and is a global health
issue, causing about 4 million deaths a year[1]. Most potentially
preventable deaths are due to blood loss. A lot of patients
with multi-trauma develop an early trauma-induced coagulop-
athy (TIC) (also called acute traumatic coagulopathy, acute
endogenous coagulopathy or acute coagulopathy of traumatic
shock). Immediate management is essential and will improve the
outcomes[2]. But the pathophysiologic mechanisms leading to
TIC remain unknown. The discovery of TIC stems from the
ﬁndings including a prolonged prothrombin time (PT) and/or
activated partial thromboplastin time (APTT) and/or
international normalized ratio (INR) at hospital admission
before the resuscitation that are associated with a three-fold to
four-fold higher mortality rate and are independently associated
with more transfusion needs, organ dysfunction, inﬂammatory
complication and intensive care unit length of stay.The changes of the coagulation function in the severe trau-
matic patients are detectable in the early stage of injury, which
support the hypothesis of an early endogenous process[3]. What
we have known is that the TIC is driven by the combination
of tissue trauma and systemic hypoperfusion which will
activate the neurohumoral system and release catecholamines,
resulting in endothelium damage that will immediately and
concurrently activate and/or inﬂuence many pathways
including the vascular endothelium, the coagulation, and
natural anticoagulation pathway; it will also affect
proﬁbrinolytic, antiﬁbrinolytic, and inﬂammatory systems. At
last, the TIC will happen[1].
As we known, coagulation is an integral part of the innate
immune system and the activation of protein C (PC) in the
endothelium system seems to be a core mechanism of TIC[4–6],
which is one of the post-traumatic inﬂammatory responses. If
the hemorrhage still continues, doctors will infuse crystalloids or
hypocoagulable blood products, like lactate ringers and red
blood cells, and these ﬂuids will cause hemodilution of the
coagulation factors, together with acidemia, consumption of
clotting factors and hypothermia and the coagulation function
will worsen, and TIC will occur[5,7,8].
Previous studies of TIC were focused on the ﬂuid resusci-
tation phase (plasma, circulating blood). Recently, many studies
are focused on a systemic pathophysiology[9]. In the following,r the CC BY-NC-ND license (http://
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TIC.
2. Deﬁning of TIC
TIC means the derangement of coagulation function due to
the tissue hypoperfusion in the severe injured patients caused by
major trauma. It is a pathophysiologic response to the tissue
injury[10]. TIC can be deﬁned by the change of the clotting time
and clot strength and also can be recognized by the prolonged
PT and/or APTT, and/or INR at hospital admission[5,10].
However, we can't just judge the clinically relevant bleeding
simply and equate it to the abnormal laboratory values. When
the true coagulopathic bleeding happens, it is always
uncontrolled, and not only restricts to the injury sites but also
becomes diffuse hemorrhage soon. Patients will die rapidly.
Distinguishing coagulopathic bleeding at the bedside by
clinical doctors is mainly based on our understanding of TIC
and we need not only careful observation but also point-to-
care test methods. However, there is an effective measure
which can help doctors to conclude the epidemiologic view of
the prevalence of TIC. Although we are not clearly under-
standing the mechanisms of TIC, we have already found some
clues, like platelet dysfunction, endothelial activation, endoge-
nous anticoagulation, ﬁbrinogen modiﬁcations, and hyper-
ﬁbrinolysis in the progress of TIC[11]. The following review will
describe the updated articles about the TIC.
3. Endothelial injury
There is the endothelial glycocalyx on the surface of the
endothelium. The endothelial glycocalyx represents a large
structure within the hemostatic system (in adults containing
approximately 1 L noncirculating plasma accounting for about
25% of the total intravascular volume) that contains signiﬁcant
amounts of heparin-like substances[12]. Degradation may induce
endogenous autoheparinization in critical ill patients[13].
As far as we know, when traumatic tissue injury occurs, the
neurohumoral system will be activated immediately and our
body will release a large amounts of catecholamines leading to
redistribution of our blood ﬂow, hemoconcentration and platelet
mobilization, then the endothelium will be activated and release
procoagulant and proﬁbrinolytic factors[14–16]. Although the
sympathoadrenal “ﬁght-or-ﬂight” response has been mostly
adapted, it may also develop to be maladaptive and at last
contribute to organ damage[9,17]. When the concentration of
catecholamine is high, it may directly damage the
endothelium, which will cause local tissue edema, swelling of
endothelial cells, cell necrosis and cell de-endothelialization[18–
21]. The downstream effects of released damage associated
molecular patterns will trigger an acute inﬂammatory response
and will cause cell damage[22–24].
4. Endothelial glycocalyx
The endothelial glycocalyx laid on the endothelial surface is
composed of glycosaminoglycans and proteoglycans. The gly-
cosaminoglycans commonly include heparin sulfates, hyalur-
onan and chondroitin sulfates. Proteoglycans usually carry
heparin sulfates and chondroitin sulfates which are called syn-
decans. The endothelial glycocalyx plays an important role,
limits protein and other soluble substance in the blood enteringthe cell junction and regulates cell adhesion and factors recog-
nition, like leukocyte and platelet interaction[11,25]. The
endothelial glycocalyx also affects the local inﬂammatory
response and the heparin sulfate component which regulates
the local cell surface coagulation system.
Syndecans are the most studied glycocalyx. Syndecan family
is comprised of four members (syndecan 1–4) and syndecan-1 is
thought to be related to trauma and is a transmembrane heparin
sulfate proteoglycan with a large extracellular domain and a
highly conserved cytoplasmic domain. It is also abundant on the
surface of almost all endothelial cells. Each syndecan has its
unique cytoplasmic domain. The base function of syndecan-1 is
as an integral membrane protein and syndecan-1 can participate
in cell proliferation, cell migration and cell-matrix interactions
via its receptor for extracellular matrix proteins[26]. In the recent
research, syndecan-1 is highly regulated during wound repair[27].
There is a study demonstrated that as a marker of endothelial
glycocalyx degradation in trauma patients, a high level of
syndecan-1 on admission is associated with high sympathoa-
drenal activity and will lead to increase in mortality. Further-
more, patients whose blood contains high level of syndecan-1
are associated with increased tissue and endothelial damage,
inﬂammation response and also with lower PC level, hyper-
ﬁbrinolysis and prolonged APTT[27].
5. PC pathway
As we have mentioned, the degradation of the glycocalyx and
tissue hypoperfusion will cause early depletion of PC, the in-
crease of plasma thrombomodulin level and the decrease of
factor V level[7]. Many studies suggest that the main principal of
TIC is the activation of the PC (aPC) pathway. When
hypoperfusion occurs, the endothelial tissue will be damaged
combined with the degradation of the glycocalyx and the PC
will be activated[28–31]. PC is a vitamin K-dependent
glycoprotein. In normal person, it circulates in the plasma;
when thrombin bond to its receptor, which is called the
endothelial PC receptor (EPCR), the PC will be activated.
Then, the PC will combine with the transmembrane
glycoprotein and we call it as thrombin-TM complex[30]. The
formation of the thrombin-TM complex will further enhance
the aPC. Once it is activated, PC has a double anticoagulant
actions and at last it will lead to TIC through the following
mechanisms: (1) acting as cofactors in the activation of factors X
and II, it inhibits the extrinsic coagulation pathway by proteo-
lytical cleaving of the peptide which bonds in activated pro-
coagulant factors V and VIII[6]; (2) it inhibits plasminogen
activator inhibitor-1 (PAI-1) and promotes ﬁbrinolysis, and it
also can reduce inﬂammation response by binding the protease-
activated receptors-1 to EPCR and decreasing leukocyte nuclear
factor kB activation[32]. At last, aPC can cleave extracellular
histones[33,34]. Cofactor protein S can also increase the activity
of the aPC. Protein S and other factors regulate the tenase
complex and this complex can inactivate the factor VIII.
Protein S also regulates the prothrombinase complex, which
cause the inactivation of factor V[6].
Totally speaking, low PC and high TM complex level are
related to poor outcomes among severe injured patients. These
patients are more likely to suffer from hypoperfusion and low
PC is also related to prolongation of PT, APTT, and hyper-
ﬁbrinolysis, in which the levels of PAI-1 is low. Some studies
use aPC–PC ratio to demonstrate the level of aPC, and reﬂect the
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complicated role affecting the pathway of coagulation in
trauma or shock patient. However, the exact mechanisms of
PC pathway activation are still needed to be veriﬁed, such as
the mechanism of triggering, the activation of PC and other
regulatory factor. Most recent studies focus on the ﬂuid
resuscitation phase of the hemostatic system, but ignore the
local site changes. When PC interacts with its 2 receptor,
thrombomodulin and EPCRs, the PC will be activated[36]. But
the details of the activation still need to be discovered.
6. Fibrinogen and hyperﬁbrinolysis
Fibrinogen is a key substance in maintaining normal hemo-
stasis. Many studies and researches have shown that low
ﬁbrinogen is associated with bad outcomes and higher mortality
rates in TIC patients and TIC animal models. Patients with TIC
who receive ﬁbrinogen supplementation seem to have better
outcomes[37].
When hemorrhage occurs, the coagulation system regulates
ﬁbrinolysis and maintains the blood clot stable for a while to
stop bleeding. High concentrations of thrombin can activate the
thrombin-activated ﬁbrinolysis inhibitor (TAFI) and PAI-1,
which inhibit the plasmin activation. But if the endothelium is
injured, the thrombin will encounter transmembrane glycopro-
tein thrombomodulin, which activates the PC and furthermore
inactivates PAI-1.
One of the major contributors of death in traumatic hemor-
rhage patients is hyperﬁbrinolysis[38,39]. A study showed that 5%
trauma patients develop severe ﬁbrinolysis when they were
tested by thromboelastometry and 57% had evidence of
moderate ﬁbrinolysis, when plasmin–antiplasmin complex
levels rise to more than twice of the normal, and the
thromboelastometry test is normal, which means majority of
trauma patients have ﬁbrinolytic activation. In the severe
injured patients, hyperﬁbrinolysis occurs early (less than 1 h)
and indicates massive transfusion requirements, coagulopathy
and hemorrhage shock-related death[38].
In recent reports, the concept of TAFI is raised. When
carboxy-terminal lysine residues on ﬁbrin are removed by
thrombin and downregulate ﬁbrinolysis, the TAFI will be acti-
vated[40]. Lustenberger et al. recently described the natural
history of the circulating TAFI activity and the plasma TAFI
antigen levels in traumatic patients[40]. They found that on
admission, the TAFI activity of patients with TIC is
signiﬁcantly decreased than the patients without TIC and this
condition will last for a while (8 days). And there is an
inverse correlation between admission TAFI activity and blood
transfusion within the ﬁrst 24 h. We still do not know the
mechanism of the phenomenon, so we need more studies on
the molecular mechanisms; it will help us to improve our
diagnostic sensitivity and make more effective clinical
interventions.
7. Platelet dysfunction
Although the mechanism of platelet dysfunction is still un-
clear, there have been some studies that assessed platelet func-
tion in trauma patients by thromboelastography-based platelet
functional analysis. We found that there are dysfunction of
platelet observed in trauma patients, even the platelet count is
normal in trauma patients[41]. The possible mechanism is usedwhen patients are critical injured, they will develop TIC,
hemorrhagic shock, hypothermia and other status. These status
will break the function of the platelet, including activation and
adhesion pathway. But there are debates on whether platelet
transfusion should be done to the patients whose platelet count
is normal, because some studies showed that patient with TIC
can receive beneﬁts from platelet transfusion, but others
showed that ﬁbrinogen and prothrombin complex concentrate
transfusion are enough and there is no need to transfuse
platelet[42].
Platelet activation and immediate adhesion, aggregation are
very important in resuscitation of trauma patients. So, the
function of platelet should be monitored during the treatment
and we should pay more attention to how to test its function and
maintain it.
8. Vicious cycle: hypothermia, acidosis and
hemodilution
Hypothermia, coagulopathy, and acidosis are the traditionally
lethal triad. In recent years, the hemodilution is added and so
called as lethal quartet, which means the uncritical overuse of
ﬂuid in hemorrhagic shock resuscitation, then the further dilu-
tion of coagulation factors will happen.
Without additional triggers, only 1% in moderate injury pa-
tients will develop coagulopathy. The percentage will rise to
39% in severe injury (injury severity score > 25) patients, when
combined with hypotension. Similarly, when patients develop
acidosis (pH < 7.1), the percentage can rise to 58% and to 98%
when injury severity score > 25, together with hypotension
(systolic blood pressure < 70 mmHg), hypothermia (temperature
< 34 C) and acidosis (pH < 7.1)[43].
Hypothermia and acidosis both can lead to coagulopathy and
they can slow down the speed of the biochemical reactions of the
plasma coagulation factor by approximately 5% with 1 C drop
in body temperature. When the individuals temperature is 30 C,
about 75% patients will stop the von Willebrand factor-
glycoprotein Ib interaction[44]. Hypothermia can inhibit the
initiation of thrombin generation and ﬁbrinogen synthesis, but
will not affect the ﬁbrinogen degradation. Similarly, when pH
is 7.2, the coagulation factor complex activities will reduce to
50% of the normal activity and to 20% at pH 6.8[7,45]. The
negatively charged phospholipids on the surface of activated
platelets help the coagulation factors to action well, but
acidosis will interfere the interplay of coagulation factors[46].
Dilution may occur both physiologically and iatrogenically.
The reversal of Starling forces and consequent shifts of inter-
stitial ﬂuid into the vascular compartment result in autodilution
of coagulation factors. And this condition is aggravated by un-
critical ﬂuid infusion. This dilution will cause consumption and
inactivation of coagulation factor and coagulation enzymes.
Ultimately, the dilutional coagulopathy is proportional to the
volume of ﬂuid administered, both in vitro and in vivo[47,48].
9. The importance of rapid diagnostics for TIC
Major traumatic patients are more likely to have haemor-
rhagic shock, require massive transfusions and have high mor-
tality rate. TIC is the key pathophysiological derangement.
When tissue is damaged, the tissue factor will expose and will
start the cascade inﬂammatory response, at last lead to shock and
hypoxia. We should imply rapid diagnostics for them and give
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diagnosis: standard coagulation tests and thromboelastography
(TEG) or thromboelastometry (ROTEM).
Standard coagulation tests include PT, APTT and INR. The
advantages of these tests include that these tests play an
important role in monitoring the bleeding status, they can help to
determine which kind of blood products should be used, they
can also reﬂect the deﬁciencies of certain coagulation factors and
can be used as the markers of TIC, and easy to be provided from
most of hospitals[49]. The disadvantages include that they are not
point-of-care assays, they can not predict the bleeding tendency
and they can not reﬂect the platelet function, thrombin genera-
tion and the whole coagulation functions. The turnaround time is
long, so the management of TIC will be delayed[6].
TEG and ROTEMmeasures the clot strength and clot forming
time and its advantages include that they can obtain the result
rapidly and reﬂect the whole laboratory clotting condition; they
are useful in the management of trauma hemorrhage due to the
quick availability of results and they can also strongly predict the
need for massive transfusion[50]. More and more studies have
shown that TEG and ROTEM may be better than traditional
coagulation tests in diagnosing TIC because we have found that
they are more sensitive than traditional coagulation tests. In
recent years, there are a lot of studies using TEG and ROTEM
as a rapid identiﬁcation of TIC. These tests use whole blood
clotting function to evaluate the coagulation status and it is
shown that trauma patients with TIC (PTr > 1.2) have a speciﬁc
thromboelastogram[51,52]. And the clot strength is reduced by 5–
10 min, which predicts the need for massive transfusion, bad
outcomes and high mortality rate[53]. But we still need further
large scale studies to prove it and we hope these tests would
become good markers of thrombin generation, even become the
gold standards in the diagnostics for TIC.
10. Conclusions
TIC is the leading cause of death in severely injured patients,
which is driven by tissue injury, and will cause systemic
hypoperfusion. In the past time, we focused on the ﬂuid resus-
citation and maintain patient's vital signs stable, but only a few
researches focused on the mechanisms. Recent studies showed
that the factors leading to hemostatic abnormalities include
hypoperfusion, inﬂammation response, and sympathoadrenal,
which break the endothelial glycocalyx, then the biomarkers of
the endothelium will be degraded; the function of the endothe-
lium is damaged, leading to local edema, and furthermore,
activating the PC pathway, starting the inﬂammatory response,
meanwhile the platelet function is limited and at last, the
hypocoagulability, ﬁbrinolysis, and endothelial hyper-
permeability develop, then TIC occurs. Researching the mech-
anism of TIC can help us to understand the process of it, which
helps doctors to recognize the lethal signs earlier and will
decrease the preventable mortality of traumatic patients.
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